Lite Strategy, Inc.
LITS
NASDAQ Capital Market1.04
USD
+0.01
- -
Lite Strategy, Inc.
LITS
(NASDAQ Capital Market)
Recent
price
1.04
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Lite Strategy, Inc. (NASDAQ: LITS) is a clinical-stage pharmaceutical company that develops novel therapies for cancer treatment alongside digital asset treasury management focused on Litecoin (LTC) accumulation; its pharmaceutical portfolio includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, zandelisib, an oral once-daily selective PI3K inhibitor, and ME-344, an intravenous small molecule inhibitor of mitochondrial oxidative phosphorylation targeting human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company engages in active treasury management to increase LTC holdings per share as its primary metric of shareholder value, positioning itself as the largest public equity vehicle for Litecoin exposure through compliant institutional-grade strategies. Lite Strategy, Inc. was incorporated in 2000, is headquartered in San Diego, California, and operates primarily in the United States within the healthcare and biotechnology sectors targeting oncology patients and institutional investors seeking digital asset access. In recent developments, the company rebranded from MEI Pharma, Inc. to Lite Strategy, Inc. in September 2025, adopting the LITS ticker and launching a new website to reflect its strategic pivot toward Litecoin treasury operations. It raised $100 million through a PIPE financing in July 2025, acquired 929,548 LTC tokens as its primary reserve asset, and formed a strategic partnership with GSR for liquidity, risk management, and treasury advisory services. Additional key changes include the announcement of a $25 million share repurchase program in October 2025 to optimize capital returns when shares trade below market net asset value, the sale of its clinical asset ME-344 to Aardvark Therapeutics, and maintenance of $12.21 million in working capital with no outstanding debt as reported in first quarter fiscal 2026 results.
Lite Strategy to Attend Panel at Litecoin Foundation Summit in Amsterdam
Lite Strategy Leads Strategic Investment in LitVM
Lite Strategy Reports Fiscal 2026 Third Quarter Results
Lite Strategy Reports Fiscal 2026 Second Quarter Results
LiTHOS Announces Board and Management Change
Lite Strategy (NASDAQ:LITS) Director James Flynn Buys 70,000 Shares